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Abstract 
Effect of temperature, age and lifespan extending interventions on Caenorhabditis elegans 
models of amyloid beta pathology    
 
 
Rachana Subhash Kelkar, B. Pharm 
 
University of Pittsburgh, 2019 
 
 
 
 
Alzheimer’s disease (AD) is an age-related neurodegenerative disease that accounts for 60-
70% of all dementia cases worldwide. The hallmark of AD is neuronal death precipitated by 
accrual of intercellular amyloid (Aβ) aggregates and intracellular neurofibrillary (NFT) Tau 
tangles. AD risk factors include age, genetics and environment. Despite intense research, the 
genetic and biochemical underpinnings of AD are poorly understood, and no drugs have been 
discovered for curing the disease. In this project, we aimed to study the impact of temperature, age 
and longevity-promoting interventions on two Caenorhabditis elegans transgenic strains modeling 
aspects of Aβ pathophysiology, by expressing full length human (1-42 amino acids) Aβ peptide in 
muscles or neurons. Since AD is an age-related disease, we first examined how age influenced the 
dynamics of Aβ-mediated phenotypes, followed by the impact of an additional stress modality- 
high temperature. As previously reported, worms expressing Aβ in muscles exhibited full body 
paralysis and mobility defects at high temperatures of 25 °C. Contrarily, the animals expressing 
Aβ in neurons did not show any paralysis but underwent distinct mobility defects under 
temperature stress. Surprisingly, we discovered that in both models the extent of pathology was 
only moderately aggravated by increasing age alone, or upon combining age and temperature 
stressors. Since aging is the biggest risk factor for AD, we also asked if genetic or chemical 
interventions known to increase lifespan could impact the phenotypes of the worm Aβ models. We 
found that a known lifespan-extending drug, promethazine•HCl, significantly delayed the onset of 
 v 
paralysis and mobility defects in the Aβ (muscle) model on day 1 of the animal. Similarly, we 
found that two known lifespan extending transcription factors, DAF-16 and NHR-49, also played 
an important role in alleviating Aβ phenotypes on day 1 and influenced the ability of 
promethazine•HCl to retard Aβ pathology. Overall, in characterizing an in vivo worm platform for 
identifying drugs and genes that impact AD, we have delineated the interlinked effects of age, 
temperature and genetic environment on Aβ pathology.  
 
Keywords: Alzheimer’s disease, C. elegans, animal model, promethazine, lifespan extending 
drug, genetics, daf-16, nhr-49, glp-1 
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1.0 Introduction  
Alzheimer’s disease (AD) is an age-related neurodegenerative disease that accounts for 60-
70% of all cases of dementia[1, 2] worldwide and is responsible for enormous social and economic 
impacts on the lives of the patients and caregivers[3]. Aging is the biggest risk factor for the 
development of the common, sporadic form of AD. AD affects around 5 million Americans[4] at 
an approximate cost of $100 billion per year.[5] It is estimated that the number of AD patients will 
reach over 14 million by the year 2050 if there are no further developments in the therapy or 
preventions of this disease[6, 7]. Despite intense research, the genetic and biochemical pathways 
that lead to AD are poorly understood and no drugs have been discovered for the cure of this 
disease. The present classes of drugs that are available for treatment are the acetylcholine esterase 
(AChE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists[2, 8, 9]. These drugs 
only provide symptomatic relief in mild to moderate AD patients and hence the root cause is not 
taken care of[9]. It is the need of the hour to develop drugs that have disease modifying or 
preventive properties. This poses a huge challenge due to lack of approved therapeutic targets and 
inadequate validated animal models[10]. 
Mechanistic molecular-genetic studies and drug screens on AD mouse models[11, 12] are 
extremely expensive and time consuming since mice live for over 2 years. Hence, moving towards 
methods and models that are short-lived and genetically amenable is an important avenue for 
unraveling AD biology and for rapid, high throughput screening (HTS) of potential therapeutics. 
In vivo models such as worms and flies can be especially valuable in terms of drug biology and 
drug mechanism of action studies. 
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1.1 Alzheimer’s disease pathology  
AD is mainly characterized by dementia. It begins with Mild Cognitive Impairment (MCI) 
that includes failure of memory and slowly becomes severe, which includes increase in confusion, 
poor judgement, language disturbance, visual complaints and agitation[13]. 95% of AD is late-
onset and is prevalent in the age groups of 60-65 years and above[14]. The remaining 5% of AD 
occurs in the age group less than 60 years. The hallmark of AD is neuronal death precipitated by 
accrual of intercellular amyloid (Aβ) aggregates and intracellular neurofibrillary (NFT) Tau 
tangles, and therapeutic development focuses on minimizing the aggregation of these proteins in 
the neurons. 
The diagnosis of the disease usually includes neuropathologic findings of 𝛽𝛽-amyloid 
plaques, intraneuronal neurofibrillary tangles (tau protein) and amyloid angiopathy[14]. The main 
molecular basis of AD is defects in protein homeostasis which lead to aggregation of misfolded 
proteins in the neurons. Two dominant theories or hypotheses have been proposed to explain AD 
mechanisms. These are the amyloid and the tau hypotheses[15]. 
The amyloid hypothesis involves a series of events that includes the process and secretion 
of the amyloid precursor protein (APP) and the imbalance caused between the production and the 
clearance of amyloid-β, which is an important factor in the development of AD[16]. Amyloid-β is 
a protein that is extremely resistant to protein degradation[17, 18]. The protein consists of two 
isoforms, 1-42 being the most common[19]. It is also hydrophobic and highly toxic[20]. Due to its 
structural configuration, this protein tends to fold into β-pleated sheets,[21] and because of this it 
has a higher tendency to aggregate and form the core of amyloid plaques[22-24] (Fig. 1).  
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Tau protein aggregation is a secondary pathogenic event that causes subsequent 
neurodegeneration[25]. There has been evidence of amyloid-β inducing tau alterations by 
promoting phosphorylation and cytoplasmic and dendritic translocation linked 
neurodegeneration[26, 27]. The function of Tau protein is to stabilize microtubules that provide 
support for axonal transport and neuronal growth.[28-30]  
 
 
Figure 1: Pathway depicting the functions of amyloid-β and the role of APP  
The amyloid precursor protein is a transmembrane protein that is cleaved by the enzyme β-secretase into 
soluble APP and the remaining transmembrane part. The transmembrane part of the protein is cleaved by γ-
secretase into amyloid-β and AICD. This enzyme can cleave Aβ protein in three different ways, at the 40th, 
42nd and 43rd amino acid. The cleavage at the 42nd amino acid generates the most toxic fragments.  
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Recently, the amyloid hypothesis and its involvement in AD have been challenged[31]. 
Alternative hypotheses suggest that the main factor causing the neurodegeneration may be the tau 
aggregates that form first. Due to the different structural conformations of these aggregates, the 
neurons are unable to function normally, leading to neuronal damage[31]. APP (amyloid precursor 
protein) has been found to trigger tauopathy[32]. Many preventative drugs that have shown 
positive results in mice models have gone further into clinical trials but almost all of them have 
failed the clinical studies. Most of these drugs generally fail the phase 3[33] clinical. Importantly 
in spite of treating the amyloid plaques, the pathology of the disease did not improve in some 
clinical trials[34]. The debate regarding primary underlying cause for AD notwithstanding, the 
involvement of Aβ and Tau in AD remains clear. However, our understanding of the cellular and 
molecular underpinnings of this disease is still poor, and a treatment/drug remains elusive. 
1.2 Risk factors of AD  
There are two different forms of AD: sporadic and familial[4, 35, 36]. The familial form 
of AD has been reported to result from mutations in at least three of the major genes. On the 
contrary, the sporadic form of AD can develop due to other genetic and environmental changes. 
The disease is further categorized into early-onset AD (EOAD) and late-onset AD (LOAD)[37-
39]. EOAD accounts for approximately 1-6% of all the cases and roughly spans between the age 
group of 30-65 years[4, 40]. On the other hand, age is the biggest risk factor for LOAD which is 
the most common form of AD. The development of LOAD is common in the age groups of 60-65 
years or older[4, 41-43]. Both LOAD and EOAD have their association in the familial form of 
AD, but approximately 60% of the EOAD have multiple cases of AD in their family[4]. The 
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sporadic form of AD is also the most common form of AD. The reasons behind developing a 
sporadic form of AD are unclear and involve a complex combination of genes, environmental 
factors and lifestyle changes. On the other hand, the familial form of AD involves mutations in 
known specific genes and also is the cause of EOAD[35, 44, 45]. 
The major risk-factors of AD are age[46], genetics and environmental changes. The 
prevailing belief, supported strongly by experimental evidence, is that with increasing age there is 
an accumulation of the above-mentioned amyloid plaques and neurofibrillary tau tangles, and these 
bodies lead to neuronal death and loss of connectivity precipitating AD symptoms. It is also 
generally acknowledged that the causative cellular and molecular changes of AD predate the 
disease symptoms by years, possibly decades[2]. Since aging is the biggest risk factor for AD, one 
attractive avenue to delay/prevent AD is to delay aging itself, and hence this is a prominent area 
of current biomedical research[47].  
As mentioned above, other important risk factors for AD include genetic mutations and 
environmental and lifestyle changes. The genetic factors include mutations in genes that lie on the 
pathway to the production and degradation of the amyloid-β[48, 49].  The three most important 
gene mutations include APP (amyloid precursor protein), PSEN I (presenilin 1) and PSEN II 
(presenilin 2)[4, 50, 51]. APP is a gene that codes for a cell surface protein that is cleaved by 
enzymes called secretases[4]. PSEN1 codes for the protein PSEN1 and this protein is a part of the 
complex γ-secretase enzyme that is involved in cleaving the APP[52].  PSEN 2 is a gene that codes 
for the protein PSEN2 which is also required for precise cleaving the APP [53]. Mutations in any 
of these genes have been shown to increase the risk to cause/ develop the disease[54-57]. Another 
genetic component involved in the disease is the presence of the ε4 allele of the gene, APOE. 
APOE codes for Apolipoprotein E, a class of enzymes involved in the metabolism of fats in the 
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body. Studies show that the presence of the APOE(ε4) allele significantly increases the risk of a 
person to develop AD[58].  
Besides age and genetics, environment and lifestyle have important roles in the 
development of AD. People who have multiple health conditions are predisposed to developing 
AD compared to healthy individuals[59-61]. In particular, individuals with obesity[61] or 
diabetes,[62] and metabolic syndrome have increased susceptibility to development of AD, as do 
ones with cardio-vascular disease (CVD) [2, 63]. 
1.3 The Caenorhabditis elegans model  
Caenorhabditis elegans (C. elegans) is a free-living, microscopic nematode. The adults are 
1 millimeter long and the newly hatched larvae are 0.25 millimeters long. They are usually 
observed under the dissecting microscope or compound microscope. C. elegans are maintained 
and grown on petri dishes with agar. These worms feed on bacteria, and in the lab are fed 
Escherichia coli (E. coli) strain OP50. C. elegans is a transparent animal and hence it is easy to 
look through the body of the animal and observe the various organs inside the animal using 
Nomarski (differential interference contrast, DIC) optics[64]. Fluorescent reporters (Fig. 2[64]) 
can be tagged to different proteins that are expressed in the worm. This makes it easier to study 
developmental defects, screen for proteins in vivo, and study the expression of proteins under 
certain conditions[64]. Importantly, the worm genome is compact and highly amenable to genetic 
manipulation. C. elegans exists as a self-fertilizing hermaphrodite (Fig. 3[64]), meaning both the 
male and the female gonad are present in the animal. Males do exist, but at a rate of less than 0.2%. 
It takes around 3 days at 25 °C for the animal to transform from being an egg to an egg-laying 
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adult. A single animal can give rise to thousands of small worms, potentially sparing an entire 
population. 
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Figure 2: Caenorhabditis elegans   
A. An image of an agar petri plate seeded with E. coli  OP50 bacteria used for growing worms placed under a 
dissecting microscope.  
B. Adult worms, embryos and larva shown under the dissecting microscope.  
C. Image of a hermaphrodite under a compound micrscope. The spermatheca, oocytes and embryos are 
clearly visible (labelled) as are the intestine and pharynx (not labelled).  
D. Image of a worm with neurons expressing GFP (green fluorescent protein). 
(Reproduced with permission from [64]) 
 9 
 
 
 
Figure 3: Anatomy of C. elegans  
A. Lateral section of an adult hermaphrodite  
B. Male C. elegans. The dorsal nerve chord and the ventral nerve chord run along the entire length of 
the animal from the nerve ring. The pharynx and the intestine of the animal are visible in green.  
C. Cross section through anterior region of the C. elegans hermaphrodite with different tissues 
highlighted.  
(Reproduced with permission from [64]) 
The life cycle (Fig. 4[64]) of C. elegans begins with the hermaphrodite laying down 
internally fertilized eggs. Eggs hatch into L1 (Larval 1) stage, further followed by L2, L3 and L4 
developmental stage. L4 is the last stage of larval life and is characterized by precise physical and 
physiological landmarks. In particular, the vulva and uterus show very stereotypical features that 
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are easily recognizable and can be used to isolate age-matched L4 larva. In an early L4 larva, the 
uterus appears ‘half-moon shaped’, whereas, late L4 larva show a characteristic ‘Christmas-tree-
shaped’ uterus and an everted vulva[64]. This is not only an important developmental landmark 
but also significant experimentally. In most cases, experiments targeting adults (such as chemical 
treatment or RNAi) are commenced at the L4 larval stage. A hermaphrodite can be distinguished 
from a male by its wider girth and tapered tail compared to a slimmer girth and fan shaped tail of 
the male. 
 
Figure 4: Life cycle of C. elegans 
The life cycle starts with the adult worm laying eggs that hatch into L1 larvae, followed by development of L1 
into L2, L3, L4 and adults.  
(Reproduced with permission from [64]) 
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C. elegans was the first multi-cellular organism whose entire genome was sequenced[65]. 
One important reason why C. elegans makes an ideal organism to study human diseases is the 
presence of highly conserved biochemical pathways between humans and worms[66, 67]. 60-80% 
of the genes are predicted to have direct or indirect homologs in the human genome and around 
40% of worm genes are associated with human diseases[2]. RNAi interference (RNAi) is 
extremely easy to undertake in worms and this has made it possible to inactivate individual genes 
and examine the consequences thereof on different parameters. The genetic and molecular 
amenability, along with high homology with human genes, have led to the development of 
numerous worms model of human disease [68-71]. These mutations help mimic the disease state 
in worms and are also easy to score based on different phenotype.  
The nervous system of the worm consists of a total of 302 neurons out of which 282 
neurons belong to the large somatic system and the remaining 20 are a part of the small pharyngeal 
nervous system. The neural networks that make up the entire nervous system of the animal have 
been visualized[72, 73]. The function of each neuron can be linked to each neural circuit. Although 
the nervous system of the worm is simple, the functions that are carried out by each neuron are 
complex and closely related to the functions carried out by human neurons[21, 73, 74]. The ease 
of maintenance, together with rapid life cycle, genetic homology and transparency makes C. 
elegans an excellent model system to study neurodegenerative and other diseases. 
1.4 Caenorhabditis elegans models of Alzheimer’s Disease  
C. elegans has become a well-utilized platform for different neurodegenerative diseases., 
due to the reasons described above. Although worms cannot recapitulate the obvious symptoms of 
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most neurodegenerative diseases such as cognitive abnormalities and neuronal death, transgenic 
strains expressing human disease proteins [such as the polyglutamine tracts (polyQ) that underlie 
Huntington’s Disease or alpha-synuclein involved in Parkinson’s Disease] exhibit cellular, 
molecular and physiological consequences that represent disease pathology. For instance, in 
worms expressing long (35+) stretches of polyQ, exposure to high temperatures causes dramatic 
polyQ aggregation (as seen in disease conditions) and subsequent paralysis of the animal. These 
phenotypes have proven to be very valuable assays to study the influence of different genes, drugs 
and environmental conditions on molecular aspects of HD pathology. Similarly, transgenic strains 
expressing Aβ (amyloid β) and Tau peptides in various C. elegans tissues have been generated, 
and are being used to dissect Aβ and Tau biology. In particular, expressing Aβ in muscles (strain 
GMC101) has been shown to make the animal susceptible to full-body paralysis upon exposure to 
high temperatures and this has proven to be a simple readout for Aβ pathology in many studies[75]. 
Similarly, Aβ expression in neurons (strain CL2355)[72] has been shown to reduce mobility in 
worms. Thus, while it is important to recognize that these strains cannot, and do not, simulate the 
human AD itself, they provide a simple biological readouts and hence are valuable platforms to 
identify genes, environmental factors and drugs that can influence cellular and molecular biology 
of Aβ and Tau.  
The two strains used in this study as models of Aβ biology are as follows:  
1. GMC101- dvIs100 [unc-54p::A-beta-1-42::unc-54 3'-UTR + mtl-2p::GFP] and 
2. CL2355- dvIs50 [pCL45 (snb-1::Abeta 1-42::3' UTR(long) + mtl-2::GFP[72]].  
The rationale for choosing these strains was to test potential anti-AD drugs and 
interventions on models where physiological phenotypes have resulted from Aβ expression in 
different tissues. The GMC101 strain was used more widely in our project since it showed a 
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stronger  and ‘easier-to-score’ phenotype[19, 76]. GMC101 L4-staged worms when exposed to a 
temperature of 25 °C underwent full-body paralysis. This paralysis was due to the aggregation of 
the human Aβ peptide in the muscles of the animal[76]. The CL2355 (Aβ neuron) strain on the 
other hand expresses the protein in the neurons of the animal and exhibits strong mobility 
defects[77]. This includes defects of thrashing in liquid, defects in chemotaxis and associated 
learning. Defects of thrashing in liquid and paralysis were the two phenotypic changes that were 
measured in these mutants for our experiments. In this project, we hypothesized that these C. 
elegans strains could be useful platform to dissect the individual and complex roles of genetic and 
environmental risk factors influencing Aβ pathology, and for screening drugs with anti-AD 
potential.  
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2.0 Material and Methods  
2.1 Nematode strains and maintenance  
The temperature sensitive mutants GMC101[27, 76] and CL2355[27, 77] along with the 
control strain Bristol N2 were used in all the experiments. All strains were obtained from the 
Caenorhabditis Genetics Centre (CGC), University of Minnesota. The strain AGP276 was 
generated by crossing the GMC101 (Aβ [muscle]) males with the CF1880[78] (daf-16;glp-1) 
double mutant hermaphrodites. The double mutant of Aβ (muscle);nhr-49 and the triple mutant Aβ 
(muscle);nhr-49;glp-1 were generated by crossing GMC101 (Aβ [muscle]) males with nhr-49;glp-
1 double mutant hermaphrodites. All strains were raised and maintained at 15 °C, and exposed to 
25 °C for the expression of the mutation. All animals were age-synchronized in the experiment by 
picking L4 (larval stage 4) worms. Age-matching with bleach was avoided to eliminate any bleach 
related stress on the animals. Animals were grown on nutrient growth medium (NGM) plates 
seeded with live E. coli OP50 bacteria.  
2.2 Solvents and chemicals  
All solvents, including DMSO (for the drug) and ethanol (for the cholesterol solution), 
were reagent grade (Fisher Scientific). Around 600 mg of the chemical, promethazine •HCl (CAS 
no. 58-33-3) was obtained from the Wipf Lab, Department of Chemistry, Chevron Science Center, 
University of Pittsburgh, Pittsburgh, Pennsylvania. M9 buffer solution was prepared by mixing 3 
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g of KH2PO4, 6 g of Na2HPO4 and 5 g NaCl in 1 L of deionized water. The mixture was sterilized 
using the autoclave on cycle 12 for liquids (60 mins at 121 °C at 15 psi). 1 mL of 1 M MgSO4 was 
added to the cooled M9 solution to prevent degradation of MgSO4. 
10x PCR (100 mM Tris, 500 mM KCl, 15 mM MgCl2 pH 8.3 dNTP mix: 25 mM/each 
Primers: 5-10 uM Taq Polymerase: approx 5U/ul) buffer was diluted to 1x using pure water and 
20 mg/mL of proteinase K was added to this mix to prepare the worm lysis buffer.  
2.3 Preparation of NGM plates  
The standard protocol[79] was used to prepare nutrient growth medium (NGM) plates. For 
the preparation of 1 L of media, 3 g of NaCl, 17 g of agar, 2.5 g of bacto peptone and deionized 
water was used to generate a volume to 1 L. This media was autoclaved on cycle 12 for liquids (60 
mins at 121 °C at 15 psi). The media was cooled in a water bath (55 °C) for 15-30 min. 25 mL of 
1 M KPO4 buffer pH 6.0 (108.3 g of KH2PO4, 35.6 g K2HPO4, deionized water to 1 L), 1 mL of 
each 1 M MgSO4, 1 M CaCl2 and 5 mg/mL of cholesterol in ethanol was added to the media later 
to prevent degradation of these compounds at higher temperature.  10 mL of media was poured in 
each 10 cm petri plate and around 6 mL of media was poured to a 3 cm petri plate. All experiments 
were performed on 10 cm plates except for thrashing which was performed on 3 cm plates. The 
plates were seeded with E. coli OP50 bacteria which was inoculated in LB (lysogeny broth) and 
incubated in a 36 °C shaker for longer than 18h. 100 μL of OP50 culture was seeded on 10 cm 
plates and 50 μL of culture was seeded on 3 cm plates. 
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2.4 Preparation of drug plates  
The drug was given to the worm through their food source. The plates were made fresh 2 
4 days before the experiment in a similar way as described above. The plates were poured and 
allowed to dry overnight. The next day, these plates were seeded with OP50 (alone), OP50 with 
0.4 % DMSO (as control), OP50 with 100 uM of the drug promethazine•HCl[80] in 0.4% DMSO 
and OP50 with 500 uM of drug in 0.4% DMSO. The seeded plates were kept overnight to dry and 
were used for the experiment the next day. A stock solution of 25 uM (to give a final concentration 
of 100 uM) and 125 uM (to give a final concentration of 500 uM) in DMSO (0.4%) was used to 
prepare a final solution of the drug in 100 uL of bacteria (seeded on each plate). One stock solution 
was used throughout a set of experiment and new solution was prepared with each new trial.  
2.5 Thrashing assay  
L4 staged worms were picked from a population that was maintained at 15 °C and 
transferred to new plates and kept at 25 °C for 24 h/ 48 h/ 96 h depending on the type of 
experiment[81]. Five separate 5-cm mini plates were marked with numbers 1-5 and filled with 1 
mL M9 solution. Worm plates were taken out of the incubator after 24 h/ 48 h/ 96 h and 20 worms 
were transferred to another unseeded mini plate to remove bacteria from the worms. After 5-10 
min one worm was transferred onto one mini plate and after 5 min the stopwatch was started for 
30 secs. Using a counter, the number of thrashes/ body bends was counted every time the worm 
moved in the opposite direction of the previous body bend.  
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2.5.1  Thrashing assay to check effect of temperature on mutant model 
Unless otherwise specified, all the strains were maintained at 15 °C. L4 (larval stage 4) 
animals were picked and subjected to temperature stress by transferring the animals to 25 °C. The 
animals were exposed to 25 °C (for 24, 48 and 96 h) and scored for thrashing as day 1, 2, and day 
4 animals (Fig. 6).  
 
Figure 5: Schematic representation of experimental Scheme 2.5.1 
2.5.2  Thrashing assay to check the effect of age on mutant model 
L4 staged animals were picked and maintained at 15 °C and 20 °C without subjecting them 
to temperature stress until day 10 of their lives. They were scored for thrashing on day 2, 4, 6, 8, 
and 10 (Fig. 7). 
 
Figure 6: Schematic representation of experimental Scheme 2.5.2 
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2.5.3  Thrashing assay to check the combined effect of temperature and age 
The worms were maintained at 15 °C. L4 stage worms were picked and maintained at 15 
°C. Animals were subjected to temperature stress on day 2, 4, 6, 8 and 10 for 24 h at 25 °C. They 
were scored for thrashing after 24 h (Fig. 8).  
 
Figure 7: Schematic representation of experimental Scheme 2.5.3 
2.6 Paralysis assay 
Similar to the thrashing assay, L4 staged worms were picked and maintained at designated 
temperature. The mutant worms were exposed to temperature stress by warming them to 25 °C for 
varied duration depending on the need of the experiment. Post exposure to temperature stress, the 
worms were scored as paralyzed or not paralyzed[81]. To confirm paralysis, the worms were 
touched with a standard sized pick. If the body of the worm moved, it was scored as not paralyzed. 
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To confirm paralysis, the worm was picked and transferred to another spot on the same plate. If 
the entire body of the worm did not move, but the head moved, the worm was still scored as 
paralyzed.  
2.7 Lifespan assay 
Wild type animals were transferred as L4’s on 10 cm treated and untreated NGM plates 
and according to standard lifespan protocol[82], they were maintained at 20 °C throughout their 
lifespan. Dead, missing and alive worms were counted everyday/ every alternate day until all the 
worms on the plates were dead. All bagged worms (a phenomenon where the eggs hatch internally 
within the parent and the larvae try to escape the parent)[83-85] were counted towards missing. 
The worms were transferred every two days onto new plates to avoid clustering of the worms on 
the plates[82]. A slightly modified lifespan assay was performed wherein the animals were 
administered with the drug from day 8 of their life. The worms were still maintained at 20 °C 
throughout their lifespan.  
2.8 Genetic crosses 
To investigate the effect of different pro-longevity genes on the AD model of C. elegans 
we wanted to introduce loss-of-function mutations in key longevity-promoting genes into that 
GMC101 strains expressing Aβ protein in the muscles. We selected genes that we and others had 
previously found to extend lifespan in the worms. daf-16[86] encodes a transcription factor DAF-
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16 (homolog of human protein FOXO3A) that plays a major role in the insulin/insulin like growth 
factory signaling (IIS) pathway[87]. This transcription factor up-regulates the expression of 
innumerable genes that contribute to the extension of the lifespan of the animal. In C. elegans, 
germline loss has been shown to dramatically increase lifespan and stress resistance, dependent on 
the presence of daf-16[86, 87]. The germline-less longevity can be re-created using a temperature 
sensitive mutant in the gene glp-1[88] that is essential for germ cell proliferation. To test if this 
longevity-extending intervention also conferred resistance to Aß pathology, we introduced the Aß 
transgene into the glp-1 background.  
Besides age and genetics, other major AD risk factors are environmental influences and 
lifestyle. Obesity increases the predisposition to developing AD as does diabetes and 
dyslipidemia[61]. We used mutants for a gene, nhr-49, that encodes the worm homolog of PPARα 
(peroxisome proliferator-activated receptor alpha), a key regulator of lipid metabolism[89-91], to 
examine the metabolic influences on Aß pathology. We crossed the mutant expressing the Aß 
protein in the muscle of the worm into different strains devoid of the following above-mentioned 
genes: daf-16, glp-1, nhr-49. A brief summary of the cross protocol is given below. 
2.8.1  GMC101 (Aß [muscle]) crossed into CF1880 (daf-16; glp-1) 
The GMC101 strain was crossed into the CF1880 (daf-16; glp-1) strain[92]. A GMC101 
male plate was prepared by transferring around 10 hermaphrodites onto 3 mini plates each and 
heat shocked in the 33 °C water bath for 4-6 h[93]. The plates were then kept at 20 °C and allowed 
to grow. Males were picked. Around 3 plates were set up with 2 plates of a 4:1 and 1 plate of a 5:2 
ratio of males to hermaphrodites. The plates were maintained at 20 °C. The worms were allowed 
to grow and 10 L4 hermaphrodites were setup, 1 worm per mini plate, to allow the individual 
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worm to propagate. It was made sure that the worms were green in color under the GFP fluorescent 
scope which ensured that the cross was successful (since only the males were GFP tagged). The 
F1 progeny was allowed to grow and 80 plates of F2 progeny were setup (1 worm per mini plate) 
and allowed to reproduce to generate progeny. The parents were transferred to another plate and 
the animals were transferred to 25 °C to confirm for glp-1 mutation. When the parents were found 
to give rise to enough (at least 30 eggs on each plate) progeny, they were lysed for the confirmation 
of daf-16 through PCR. The new mutant was named as AGP276 and frozen in the worm library. 
 
 
Figure 8: Cross of GMC101 into AGP22 
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2.8.1  GMC101 (Aß [muscle]) crossed into AGP22 (nhr-49; glp-1) 
The GMC101 strain was crossed into the AGP22 (nhr-49; glp-1) strain. A GMC101 male 
plate was prepared by transferring around 10 hermaphrodites onto 3 mini plates each and heat 
shocked in the 33 °C water bath for 4-6 h[93]. The plates were then kept at 20 °C and allowed to 
grow. Males were picked. It was made sure that the worms were green in color under the GFP 
fluorescent scope which ensured that the cross was successful (since the males were GFP tagged). 
Around 3 plates were set up with 2 plates of a 4:1 and 1 plate of a 5:2 ratio of males to 
hermaphrodites. The plates were maintained at 20 °C. A second cross was performed by picking 
males on the cross plate and picking L4 stage hermaphrodites of the AGP22. The ratio was 10 
males to 3 hermaphrodites. The worms were allowed to grow and 10 L4 hermaphrodites were 
setup, 1 worm per mini plate, to allow the individual worm to propagate. The F2 progeny was 
allowed to grow and 80 plates of F3 progeny were setup (1 worm per mini plate) and allowed to 
reproduce to generate progeny. The parents were transferred to another plate and the animals were 
transferred to 25 °C to confirm for glp-1 mutation. When the parents were found to give rise to 
enough (at least 30 eggs on each plate) progeny, they were lysed for the confirmation of nhr-49 
through PCR. 
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Figure 9: Cross of GMC101 into AGP22 
2.8.2  Molecular diagnostic tests for daf-16 and nhr-49 
The glp-1(e2144ts) mutation causes a temperature-sensitive loss of fertility, and this 
sterility was used as the diagnostic test to identify glp-1 mutation in crosses. The daf-16(mu86) 
null mutant we used here carried a 10980 bp deletion[94] in the daf-16 genes that resulted in a 
complete loss of protein function. The nhr-49(nr2041) mutation was a 893 bp[94] deletion that 
eliminated part of intron 3, all of exon 4 and some of exon 5 from the K20C3.6c transcript[95]. 
To confirm the mutation in crosses, PCR (polymerase chain reaction) was used to amplify 
the piece of DNA of interest. To carry out PCR confirmation the worms were first lysed[96] using 
5 uL of worm lysis solution (995 uL of 1X PCR buffer with 5 uL of proteinase K) for normal PCR 
(1 parent adult worm/tube) and 10 uL of worm lysis buffer (around ~5 adult worms/tube) for 
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population PCR. The tubes were kept at -80 °C for 15-30 min. The worm lysis program cycle (60° 
60’, 95° 15’, 4° hold) was used on PCR.  
5 uL of this lysate solution was added to 20 uL of the PCR mix (Table 1). Post worm lysis, 
GoTaq and primers were added specific to daf-16 and the PCR cycle (94° 3’, [94° 45”, 55° 30”, 
72° 1’30”]x29, 72° 10’, 4° hold) was carried out. PCR mix differed from gene to gene.  
The PCR mix for daf-16 was as follows: 
Table 1: Formula of PCR mix for daf-16 mutation 
INGREDIENT  AMOUNT/TUBE (uL) 
GoTaq 12.5 
KL4 1.5 
KL5 1.5 
KL15 1.5 
KL32 1.5 
ddH2O 1.5 
Worm lysate 5 
TOTAL 25 
 
For nhr-49 confirmation using PCR, the same steps were followed except for the program 
used in the PCR machine. The program for nhr-49 (95° 2’, [95° 30”, 62° 30”, 72° 1’]x40, 72° 10”, 
4° hold) was used on the PCR machine. This program was optimized by Dr. Ghazi.  
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The PCR mix for nhr-49 was as follows:  
Table 2: Formula of PCR mix for nhr-49 mutation 
INGREDIENT  AMOUNT/TUBE (uL) 
GoTaq  12.5 
Mut F  0.5 
R1  0.5 
R2 0.5 
ddH2O 6 
Worm lysate  5 
TOTAL  25 
 
The GoTaq contained all the primers and the nucleotides. The strength of GoTaq was 2X 
hence half the actual amount of it was used in the PCR mix. 
Agarose gel electrophoresis was carried out on PCR products and it was used to separate 
DNA fragments. 1 g of agar was dissolved in 100 mL of buffer solution. 15 uL of ethidium bromide 
was used to tag DNA. This chemical intercalates in DNA[97] and allows to visualize different 
bands in the image reader. The gel was analyzed in a Biorad Gel Doc EZ Imager and on the Image 
Lab 6.0 software.  
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Figure 10: Mutant confirmation using gel electrophoresis post PCR  
A. Inverted images of confirmation of daf-16 mutation. The first three lanes are control with WT (437 bp) in 
the first, daf-16 (657 bp) mutant in the second and mix of both in the third. There were four lines of the 
daf-16 mutant obtained. All the lines were homozygous for the daf-16 mutation.  
B. Confimation of nhr-49 (250 bp) mutation with first three lanes having the WT (350 bp) control and mix 
of both. 3 lines were obainted that were homozygous for the mutation. 
2.9 Statistical analysis  
Statistical analysis was conducted in GraphPad Prism version 8.0.1 (145). Unless otherwise 
stated, data were analyzed using unpaired t-test. All data were reported and shown as mean±SD 
(Standard Deviation). A survival curve for lifespan assay was plotted in the OASIS 2 software. 
For the lifespan assay, Kaplan-Meier statistics with Log-Rank Test were utilized. 
A B 
 27 
3.0 Results  
3.1 Characterization of the AD mutant models of C. elegans  
The GMC101 and CL2355 strains’ phenotypes have been well documented. However, how 
these features are impacted by age or temperature stress (or both) has not been investigated in 
detail. We characterized the mutant models by the effects of age and temperature individually and 
then by examining them together, since both are important risk factors for AD. The rationale 
behind testing the temperature effect was to check if temperature stress would cause protein 
aggregation in the muscles and neurons of these mutants, respectively. Temperature stress was 
found to disrupt the protein homeostasis in the animals which would in turn cause the misfolding 
of the protein causing it to aggregate and bring about phenotypic changes in the animal. We also 
wanted to test if combining age and temperature stress might result in aggravation of Aß pathology. 
 
3.1.1  Effect of temperature on paralysis and mobility features 
We observed that exposing the GMC101 worms showed a significant decline in the number 
of thrashes at a very early stage in the animals’ life. The thrash number was seen to be significantly 
lower in GMC101 animals compared to the WT animal on day 2 (Fig. 10-A). Similarly, a 
significant decline in the thrash number was observed in CL2355 strain on day 2 and further 
decrease was seen on day 4 (Fig. 10-B). This was in accordance with previous reports, and led us 
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to conclude that temperature stress aggravates Aβ pathology whether expressed in the neurons or 
in the muscle.  
 
 
Figure 11: Effect of temperature on mobility features  
A. Effect of temperature stress on thrashing assay of GMC101 worms  
B. Effect of temperature stress on thrashing assay of CL2355 worms  
Experiments were performed in two independent trials with n=20 per trial. Student’s unpaired t-test was 
used to carry out statistical analysis. * indicates p<0.05, *** p<0.0001 
 
With respect to paralysis, around 60% of the GMC101 worms were found to be paralyzed 
under temperature stress of 25 °C. On the contrary, the CL2355 worms were not seen to be 
paralyzed at all. Hence, aggregation of the protein within the neurons does not appear to show a 
strong phenotype as opposed to when the aggregation took place in the muscle. However, this 
strain has been reported to exhibit behavioral deficits including defects in to associated learning of 
the association of food and odorant [77]. 
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3.1.2  Effect of age on paralysis and mobility features  
Since age is the single biggest risk factor for AD, we hypothesized that the GMC101 strain 
would exhibit pathology as animals aged, without exposure to high temperature, or that 
temperature stress would accelerate paralysis in older animals. However, surprisingly this was not 
the case. Older animals that were maintained at lower temperatures throughout their lives (15 °C 
and 20 °C) showed mobility comparable to wild-type control animals. GMC101 did not show any 
further decrease in the number of thrashes as old animals at 15 °C and 20 °C compared to WT 
animals. The thrashing number in GMC101 strain was consistently lower than that of the WT at 
every age, suggesting that the presence of the Aβ protein induces aggregation that is sufficient to 
cause loss of mobility (Fig. 10-A and 10-C), and increasing age did not aggravate this dramatically. 
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Figure 12: Effect of age on mobility features 
A. and C. Effect of thrashing on GMC101 worms when maintained at 15 °C and 25 °C respectively    
B. and D. Effect of thrashing on CL2355 worms maintained at 15 °C and 25 °C respectively  
Experiments were performed in two independent trials with n=20 per trial. Student’s unpaired t-test was 
used to carry out statistical analysis. * indicates p<0.5, ** p<0.01 
Surprisingly, the CL2355 strain showed mobility comparable to that of WT in young 
animals (day 2 and day 4) adults but showed improved mobility on days 6, 8, and 10 (Fig. 10-B 
and 10-B). Thus, it appears that while the presence of  the Aβ peptide itself in muscles or neurons 
is sufficient to destabilize mobility, the effects are not dramatically impacted as the animal ages. 
It was possible that longer exposures to high temperatures are required to bring about stronger 
phenotypic changes in the mutants. 
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3.1.1  Effect of temperature and age on paralysis and mobility features  
We wanted to analyze the combined effect of temperature and age on these Alzheimer’s 
mutants and wanted to see if age and temperature stress together caused a further degradation in 
the mutant phenotype compared to the WT animals. Hence, we exposed the animals to temperature 
stress at different stages of the worms’ life. Worms were exposed to 25 °C as day 2, 4, 6, 8 and 10 
and scored for thrashing 24 h post higher temperature exposure. The animals were maintained at 
15 °C before exposing them to higher temperature of 25 °C.  
As Alzheimer’s is an age-related disease[46], we expected that the older animals might 
show defects in their mobility much earlier than the younger animals when exposed to temperature 
stress. But to our surprise, we observed that there was no difference between the thrashes in older 
(day 4 and 6) and much older animals (day 8 and 10).  
GMC101 worms showed a decrease in the number of thrashes post day 9 but the decrease 
was not significant (Fig. 12-A). Similar to GMC101 worms, CL2355 showed also a decrease in 
the number of thrashes post day 7, but the difference was not significant (Fig. 12-B).  
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Figure 13: Effect of temperature and age on mobility features 
A. Effects of GMC101 worms on thrashing when older animals are exposed to higher temperatures (25 °C)  
B. Effects of CL2355 worm son thrashing when older animals are exposed to higher temperature (25 °C) 
Experiments were performed in two independent trials with n=20 per trial. Student’s unpaired t-test was 
used to carry out statistical analysis. 
 
We also exposed older animals (on day 2, day 4 and day 6) to temperature stress (25 °C) 
and we were surprised to see that none of them were paralyzed after 48 h. This might suggest that 
the sole presence of Aβ in the worm has no phenotypic effect on the animal. Hence, exposing older 
animals to higher temperature of 25 °C had no significant effect on the phenotype, suggesting that 
this model of C. elegans might not be an accurate representation of the Aβ pathology. The results 
were consistent with the previous conclusion (Fig. 11), where there was no decrease in the number 
of thrashes in the older animals as compared to the younger ones.   
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Figure 14: Effect of old age and temperature on paralysis of GMC101 animals  
The worms were transferred to higher temperature on day 2 (A), day 4 (B), day 6 (C) and none of them were 
seeme to be paralyzed. The experiments were performed in three independent trials with n=20. Student’s 
unpaired t-test was used to carry out statistical analysis. 
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3.2 Screening of drugs on the mutant models 
3.2.1  Screening of promethazine•HCl on wild type C. elegans  
A previous study[80] conducted a high throughput screening (HTS) of drugs that were 
already marketed for different disease conditions to check their lifespan-extending properties in C. 
elegans. The categories of drugs included various anti-histamines, calcium channel blockers, anti-
biotics, adrenergics, hormones, potassium channel blockers, etc. One of the lifespan-extending 
drugs identified in this study was promethazine•HCl (CAS NO.: 58-33-3), an anti-histamine 
indicated for allergic conditions and for motion sickness. In the published report, it was found to 
extend the lifespan of C. elegans by 32%[80]. Since AD is an age-related disorder, we asked if 
increasing lifespan might delay the onset of the disease or prevent it and tested the effect of this 
drug on the Aß pathology in Alzheimer’s mutants. 
We reproduced the lifespan assay on the WT animals on solid media[82] and on different 
concentrations (33 uM and 100 uM in one experiment and 100 uM and 500 uM in the other) of the 
drug (Fig. 14 and 15). It was observed that there was no significant difference in the extension of 
lifespan when the worms were treated with a lower concentration of drug (33 uM) but there was a 
significant increase in the longevity of the animal when treated with a higher concentration of the 
drug (100 uM) (Fig. 14).  Since AD is detected later in life and as treatment begins thereafter, we 
wanted to check if  
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Figure 15: Survival curve of WT (N2) animals at different concentration of promethazine•HCl   
This figure is a representation of one trial with n=100 per condition. Kaplan Meier (log-rank test) statistics 
were used to carry out statistical analysis for lifespan assays. P 500 uM vs N2 DMSO 0.0085**   
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Figure 16: Survival Curve of WT (N2) animals at different concentration of promethazine•HCl 
3.2.2  Screening of promethazine•HCl on GMC101 worms  
First, we confirmed that promethazine•HCl extended the lifespan of WT C. elegans. Next, 
we tested to see if this lifespan extending drug improved Aß pathology. The lower drug 
concentration of 33 uM had no significant difference compared to the solvent-only DMSO control 
and hence the concentration of the drug was increased to 500 uM. The drug was administered to 
20 worms on each plate, and the worms were scored for thrashing and paralysis.  
3.2.2.1 Effect on thrashing assay  
There was no significant difference in the number of thrashes of WT and the GMC101 
worms. It could be observed that the effect was higher in the GMC101 worms treated with the 
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drug compared to the WT worms treated with the drug (Fig. 16-A and 16-B) when compared to 
their respective DMSO controls. There was no significant difference between the treatment group 
and the DMSO control group in the WT animals. Although the thrash number was higher in the 
treated GMC101 worms compared to the DMSO control, the effect was insignificant.  
 
 
Figure 17: Effect of promethazine•HCl on thrashing of GMC101  
A. Thrashing of WT worms when treated with promethazine•HCl 
B. Thrashing of GMC101 worms when treated with promethazine•HCl 
Experiments were performed as two independent trials with n=20. Student’s unpaired t-test was used to 
carry out statistical analysis. * indicates p<0.05 
3.2.2.2 Effect on paralysis assay  
The GMC101 worms were treated with two different concentration of drugs – 100 uM and 
500 uM. These concentrations were kept constant from the previous survival assay. The worms 
treated with the higher concentration of the drug (500 uM) showed a significant decrease in the 
percentage of paralyzed worms. There was no significance seen in the worms that were treated 
with a lower concentration (100 uM) of the drug (Fig. 17). This demonstrated that the effect was 
dose dependent. The comparison was done between the treated and the DMSO control.  
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Figure 18: Effect of promethazine•HCl on paralysis of GMC101 
The mutant was treated with two different concentration of the drug. Experiments were performed as two 
independent trials with n=10 per conditions. Student’s unpaired t-test was used to carry out statistical 
analysis. * indicates p<0.05 
3.2.3  Screening of promethazine•HCl on CL2355 worms  
Promethazine•HCl was found to have a positive effect on the muscle Aβ model of C. 
elegans. Since, in AD, there are amyloid plaques that are observed in the neurons, we wanted to 
observe the effect of the drug in other mutant that expressed the Aß protein in the neurons of the 
worm. The only phenotype that we focused on was the defect in thrashing.  
3.2.3.1 Effect on thrashing assay  
The worms were treated with two different drug concentrations of drug – 100 uM and 500 
uM. Overall, the CL2355 mutants on drug had a higher thrash number compared to the WT 
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animals. Hence, the drug promethazine•HCl improved the Aß pathology. The thrash number for 
CL2355 worms was significantly higher for the treated group compared to the DMSO control. 
(Fig. 18-A and 18-B). Surprisingly, the drug was also seen to have some effect on the WT animal. 
 
 
 
Figure 19: Effect of promethazine•HCl on thrashing of CL2355 
A. Thrashing of WT worms when treated with promethazine•HCl 
B. Thrashing of GMC101 worms when treated with promethazine•HCl 
Experiments were performed as two independent trials with n=10 in each group. Student’s unpaired t-test 
was used to carry out statistical analysis. * indicates p<0.05 
3.3 Impact of pro-longevity genes on Aß pathology and the ability of promethazine•HCl to 
ameliorate it 
Genetic predisposition is a major risk-factor of AD. Mutations in various genes can lead to 
acceleration of, or protection against, the onset of AD[98, 99]. For instance, mutations in genes 
like PSEN1 (presenilin 1) and PSEN2 (presenilin 2) which are directly or indirectly involved in 
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cleaving the Aß peptide, are involved in familial AD. These mutations cause the Aß protein to get 
accumulated in the neurons and hence makes them dysfunctional[48].  To check the effect of 
various pro-longevity genes, we introduced mutants of these genes into the GCM101 and CL2355 
backgrounds. crosses and generated the mutants. We then wanted to test if administering the drugs 
and absence of these genes might have any effect on the Aß pathology. 
There are a number of genes that contribute to the longevity of C. elegans and two of the 
most important transcription factors that were found to contribute to the longevity of glp-1 
(germline less mutants) animals were daf-16  and nhr-49[86, 87, 100]. Hence, we wanted to 
investigate if these transcription factors would have any role to play in the Aβ pathology.  
3.3.1  Screening of promethazine•HCl on AGP276 (Aß;daf-16) model of AD 
The double mutant was obtained by crossing the Aß (muscle) expressing mutant into the 
double mutant of daf-16:glp-1. We wanted to investigate if Aß pathology is associated with the 
IIS/IGF (Insulin/Insulin like growth factor) pathway. Hence, we used mutants that were loss of 
function daf-16. We obtained this mutant by crossing as described in the methods section.  
3.3.1.1 Effect on thrashing assay  
The double mutant was found to have a deteriorating effect on the health-span compared 
to the GMC101 worms suggesting that the absence of daf-16 makes it worse. Aligning with the 
effects of the mutant model of AD, the drug improved the health of the double mutant. The absence 
of daf-16 does not make any significant difference in the thrashing, suggesting that the drug might 
act through this pathway or influence it (Fig. 19-A and 19-B).  
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Figure 20: Effect of promethazine•HCl on thrashing of AGP276 (Aβ (muscle);daf-16) 
A. Thrashing of GMC101 worms when treated with promethazine•HCl  
B. Thrahsing of AGP276 (Aβ (muscle);daf-16) when treated with Promethazine HCl  
Experiments were performed as two independent trials with n=10 in each group. Student’s unpaired t-test was 
used to carry out statistical analysis. 
3.3.1.2 Effect on paralysis assay 
The other important parameter was to examine the effect of paralysis on these double 
mutants with and without the different concentrations (100 uM and 500 uM) of the drug. The effect 
of paralysis was not so clear on the double mutant, although the group treated with the drug was 
observed to have less paralysis. The trend in the double mutant was similar to the control mutant 
model of AD. Also, the percent paralysis with the treated group in the mutant was comparable to 
the percent paralysis in the control worms. Hence, we concluded that daf-16 could be an essential 
gene in bringing about the positive effect of the drug.  
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Figure 21: Effect of promethazine•HCl on paralysis of AGP276 (Aβ (muscle);daf-16)  
A. Thrashing GMC101 worms when treated with promethazine•HCl  
B. Thrashing AGP276 (Aβ (muscle);daf-16) worms when treated with promethazine•HCl  
Experiments were performed as three independent trials with n=30 in each group. Student’s unpaired t-test 
was used to carry out statistical analysis. * indicates p<0.05 
3.3.1  Screening of promethazine•HCl on Aß(muscle);nhr-49  
As mentioned above, we wanted to investigate the role of different genes in the Aß 
pathology and hence, we selected a couple of transcription factors that were involved in the 
lifespan extension. One of the lifespans extending genes is nhr-49[100]. Hence, we crossed the 
mutant having a LoF (loss of function) mutation into AD model of C. elegans and carried out the 
thrashing and paralysis assay.  
3.3.1.1 Effect on Thrashing assay  
The effect of the drug on these mutants was unclear. The trend was consistent with respect 
to the control group. The GMC101 worms that were treated with the higher concentration (500 
uM) of the drug was having high number of thrashes compared to the control DMSO groups. On 
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the other hand, in the Aß mutant with a LoF (loss of function) nhr-49, there was an increase in the 
number of thrashes with the control DMSO group. With the treatment group, the variability seen 
was much higher. It may be concluded that absence of this gene might have a deteriorating effect 
on the pathology of the disease, and treatment with the drug has no significant effect in improving 
the Aß pathology. 
 
 
Figure 22: Effect of promethazine•HCl on thrashing of double mutant (Aβ (muscle);nhr-49) 
A. Thrashing of GMC101 worms when treated with promethazine•HCl  
B.  Thrahsing of Aβ (muscle);nhr-49 worms when treated with promethazine•HCl  
Experiments were performed as two independent trials with n=10 in each group. Student’s unpaired t-test 
was used to carry out statistical analysis. 
3.3.1.2 Effect on paralysis assay  
A paralysis assay was performed on these mutants to have a clear idea of how nhr-49 loss 
of function performed in an Aβ environment. Like the thrashing assay, the trend in paralysis was 
unclear and hence it was very difficult to conclude from the results due to high variability. 
Consistent with the results of thrashing assay, the DMSO control worms performed better than the 
lower concentration (100 uM) drug treatment group. DMSO control group in both the thrashing 
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and paralysis assay was found to improve Aβ pathology and hence it was concluded that DMSO 
had some relationship with nhr-49 in an Aβ environment.  
 
Figure 23: Effect of promethazine•HCl on paralysis of double mutant (Aβ (muscle);nhr-49) 
A. Effect of drug on control mutant model of AD  
B. The effect of the drug on double mutant Aβ(muscle);nhr-49 
Experiments were performed as two independent trials with n=10 in each group. Student’s unpaired t-test 
was used to carry out statistical analysis. 
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4.0 Discussion and Conclusion 
Temperature stress causes a proteotoxic environment that leads to aggregation of Aβ 
protein in the muscle irrespective of age. We observed that exposing the animals to higher 
temperature or to temperature stress aggravates Aβ pathology by accumulation of Aβ protein in 
the muscle of one mutant (GMC101) and in the neuron of the other mutant (CL2355). Since AD 
is an age-related disorder, we hypothesized that age would worsen the Aβ pathology in both these 
mutant models (GMC101 and CL2355). GMC101 worms inherently showed reduced mobility 
defects compared to the WT animals. With age, these worms were found to have decreased 
mobility, but the effect was comparable to the WT animals. On the other hand, the CL2355 strain 
showed a decline in the mobility with age but had improved mobility than the WT animals.  
We further investigated the effect of temperature and age together and expected the effect 
to be additive. However, it was observed that AD did not worsen with age in this model of C. 
elegans. This result was aligned with our previous observation of age not having any deteriorating 
effect on AD. This suggested the fact, that the “so called” Aβ model of C. elegans only expressed 
the protein in the developmental stages in the worms’ life and hence had nothing to do with the 
component of age. But, temperature stress (25 °C) was enough to bring cause defects in protein 
homeostasis that brought about aggregation of this protein in the muscle of the animal. The 
aggregation of this protein mimicked the Aβ pathology. Hence, this could be used as an Aβ 
pathology model to screen various potential drug candidates.  
Promethazine•HCl has the potential to improve Aβ pathology in the mutant model. After 
establishing a model that resembled the Aβ model, we tested promethazine•HCl on C. elegans. 
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Promethazine•HCl is a marketed anti-histamine that is indicated in allergic conditions and in 
motion sickness[101, 102]. This drug has been shown to extend lifespan of C. elegans and our 
experiments on WT lifespan confirmed the previously established results. We hence tested the 
drug on Aβ models of C. elegans and we observed that it improved Aß pathology by delaying the 
paralysis in the mutant expressing the protein in the muscle (GMC101) and by increasing the 
number of thrashes in the both the mutant expressing the protein in the muscle and the neuron 
(GMC101 and CL2355). 
daf-16 and nhr-49 play an important role in the Aβ pathology and daf-16 might have a role 
to play in the mechanism of promethazine•HCl. We found that the Aβ;daf-16 double mutant had 
a deteriorating health-span (thrashing and paralysis) when compared to the GMC101 worms. This 
suggested that DAF-16 is an important transcription factor for the improvement of Aβ model of 
Alzheimer’s disease. When these double mutants were treated with promethazine•HCl, there was 
no significant change in the health-span of the worms when compared to the GMC101 worms. 
This suggested that the DAF-16 transcription factor is necessary for the effective action of the 
drug.  
The Aβ;nhr-49 double mutant showed deteriorating effects in thrashing and paralysis when 
compared to the Aβ model. When these mutants were treated with promethazine•HCl, the results 
were highly variable. It was seen that the DMSO controls had a positive effect, which was 
comparable to the higher concentrations (500 uM) of the drug. On the other hand, the lower 
concentration (100 uM) of the drug had no effect on both thrashing and paralysis. This makes the 
interpretation complicated and we can conclude that NHR-49 (transcription factor), 
promethazine•HCl and DMSO have some effect on each other which is visible in the phenotype 
of the animal. 
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Overall, the Aβ model of C. elegans helps us understand one small aspect of Alzheimer’s 
disease. It takes into consideration complex effects of the disease pathology. We could also mimic 
the complex neurodegenerative pathology. Working with this model allows us to potentially screen 
thousands of drug candidates and narrow them down to a handful that can be tested in mice. 
Another important reason to support this model would be the in vivo aspect of the studies that high 
throughput screens don’t provide.  
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5.0 Future directions  
Once we established a model based on the phenotypic changes of the mutants, we could 
check the mRNA and protein levels in the animal. Tagging the amyloid-β with a GFP (green 
fluorescent protein) would be another way of quantifying the protein of interest. This would help 
us visualize the protein aggregation and quantify its expression. We could also perform sequencing 
of worms under various stressors and analyze the different set of genes that are upregulated or 
downregulated to get a clear idea of how the genetics are influenced by presence of the Aβ protein. 
Once we have these set of genes, we could select a few and examine the effect of alterations in 
these genes in an amyloid rich environment. We could also combine different mutant models of 
Aβ and tau to confirm the reconsiderations of the amyloid hypothesis.  
 Extending this model to different drug candidates would be the next step in the project, 
once a robust model is established. There have been high throughput screens that have been carried 
out on worms, but most of these are carried out on WT animals. Performing high throughput 
screens on our Aβ model would help us to evaluate the potential of these drug candidates against 
this pathology. The drug classes that can be tested are those influencing the mitochondrial 
homeostasis, drugs that are already established to have an influence on the studied transcription 
factors – DAF-16 and NHR-49, and drugs that have found to impact heat shock proteins in the 
worm. The rationale behind testing these drugs would be that all these have an influence on the 
Aβ pathology in one way or the other.  
In general, although it is almost next to impossible to mimic the exact AD environment 
and trying to treat the disease, C. elegans provides us a platform to mimic the genes involved in 
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the complex cellular biology of Aβ pathology. It is a useful model for understanding the 
convoluted biology and helps us study the therapeutic effect of the various potential molecules for 
Aβ pathology prevention. Lastly, this model as a whole, teases out the complicated nature of Aβ 
pathology and allows us to test various effects rapidly. Hence, the focus of this project was mainly 
to develop, establish and validate a C. elegans model to test potential drugs that would be able to 
help prevent the disease.  
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Appendix A Abbreviations  
Term                           Abbreviation  
AD                               Alzheimer’s disease  
C. elegans                    Caenorhabditis elegans  
Aβ                                Amyloid beta  
PCR                             Polymerase chain reaction  
nhr-49                          Nuclear hormone receptor  
EOAD                          Early-onset AD  
LOAD                          Late-onset AD  
PPARα                         Peroxisome proliferator-activated receptor alpha 
AChE                           Acetyl choline esterase  
NMDA                         N-methyl-D-aspartate  
HTS                              High throughput screening 
MCI                              Mild cognitive impairment  
ROS                              Reactive oxygen species  
APP                              Amyloid precursor protein  
NFT                              Neurofibrillary tangles  
AICD                            APP intracellular domain  
PSEN1                          Presenilin 1 
PSEN2                          Presenilin 2  
APOE                           Apolipoprotein E  
DIC                               Differential interference contrast  
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E. coli                           Escherichia coli 
L1                                 Larval stage 1  
L2                                 Larval stage 2 
L3                                 Larval stage 3  
L4                                 Larval stage 4 
RNAi                            RNA interference  
NGM                            Nutrient growth medium  
CGC                             Caenorhabditis genetics center  
DMSO                          Dimethyl sulfoxide  
MgSO4                          Magnesium sulfate  
HCl                               Hydrochloric acid  
NaCl                             Sodium chloride 
dNTP                            Deoxy nucleotide triphosphate  
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Appendix B Reagents  
 
Figure 24: Structure of promethazine•HCl 
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